Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Metastatic Colorectal Cancer (mCRC)
100%
Colorectal Cancer
68%
Gemcitabine
52%
Phase II Study
52%
Overall Survival
46%
Bevacizumab
42%
Chemotherapy
42%
Oxaliplatin
37%
Tumor
36%
Phase I Study
36%
Phase II Trial
30%
Capecitabine
29%
Progression-free Survival
29%
Advanced Solid Tumors
28%
5-fluorouracil (5-FU)
28%
Programmed Death-ligand 1 (PD-L1)
26%
Median Overall Survival
25%
Stable Disease
25%
Irinotecan
25%
Treatment-related Adverse Events
23%
Solid Tumors
22%
Maximum Tolerated Dose
21%
Cetuximab
21%
Confidence Interval
21%
Metastatic Pancreatic Ductal Adenocarcinoma
21%
Hazard Ratio
20%
Gene Expression
20%
Antitumor Activity
20%
Leucovorin
19%
Neutropenia
19%
Pembrolizumab
19%
Advanced Malignancies
18%
Median Progression-free Survival
18%
Non-Hispanic White
18%
Radiation Therapy
18%
Tolerability
17%
Previously Treated
17%
Partial Response
16%
Pharmacokinetics
16%
Recommended Phase 2 Dose
16%
Resectable Pancreatic Cancer
16%
KRAS mutation
15%
Trifluridine-tipiracil
15%
Dose-limiting Toxicity
15%
Phase 1b Study
14%
Anemia
14%
Cisplatin
14%
Phase I Trial
14%
Molecular Landscape
14%
Immune Checkpoint Inhibitors
14%
Metastatic Pancreatic Cancer
14%
Clinical Trials
14%
Imatinib Mesylate
14%
Gastrointestinal Cancer
14%
Southwest Oncology Group
14%
Atezolizumab
14%
Dose Escalation
14%
Targeted Therapy
13%
Locally Advanced
13%
Advanced Colorectal Cancer
13%
Overall Response Rate
12%
Gastric Cancer
12%
FOLFOX
12%
Dose Level
12%
Pancreatic Cancer
12%
Pancreatic Ductal Adenocarcinoma
12%
Adjuvant Therapy
12%
Colorectal Cancer Patients
12%
Adverse Events
11%
Microsatellite Instability-high (MSI-H)
11%
Oncology
11%
Elderly Patients
11%
Advanced or Metastatic
11%
Wild-type KRAS
11%
Placebo
11%
Diarrhea
11%
Nausea
11%
Refractory Solid Tumors
11%
Clinical Practice Guidelines
11%
Microsatellite Stable
10%
Colon
10%
Paclitaxel
10%
Objective Response Rate
10%
Phase 1 Trial
10%
Survival Analysis
10%
Therapeutic Strategies
10%
Clinical Activity
10%
Neoadjuvant Chemoradiotherapy (nCRT)
9%
Docetaxel
9%
Expansion Cohort
9%
Refractory Malignancy
9%
Randomized Controlled Trial
9%
Tumor Microenvironment
9%
Chemoradiation
9%
Thrombocytopenia
9%
Colorectal Liver Metastases
9%
Locally Advanced Rectal Cancer
9%
Reovirus
9%
Biliary Tract Cancer
9%
Randomized Phase II Trial
9%
Chemoradiation Therapy
9%
Unresectable Hepatocellular Carcinoma
9%
Imatinib
9%
Aurora Kinase A (AURKA)
9%
Leukemia
9%
Mesalamine
9%
Alisertib
9%
Pathological Complete Response
9%
Ulcerative Colitis
9%
Medicaid Expansion
9%
Gastroesophageal Adenocarcinoma
9%
Margetuximab
9%
Pancreatic Carcinoma
9%
Anal Squamous Cell Carcinoma
9%
American Indian or Alaska Native
9%
Racial Disparities
9%
National Cancer Database
9%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
9%
Improved Survival
8%
Patients with Colorectal Cancer
8%
NCCN Guidelines
8%
Breast Cancer
8%
Progressive Disease
8%
Advanced Biliary Tract Cancer
8%
Borderline Resectable
8%
Patient Demographics
8%
Treatment Algorithm
8%
Systemic Therapy
8%
Response Rate
8%
Fluorouracil
8%
Leukopenia
7%
Twice Daily
7%
White People
7%
Response Evaluation Criteria in Solid Tumors (RECIST)
7%
Hypertension
7%
Treatment Options
7%
Dosing Regimen
7%
Cancer Patients
7%
Colon Cancer
7%
Safety Activity
7%
Metastatic Disease
7%
Complete Response
7%
Predictive Biomarker
7%
TAS-102
7%
Deficient Mismatch Repair (dMMR)
7%
Mitogen-activated Protein Kinase
7%
Refractory Cancer
7%
Adenocarcinoma
7%
Small Bowel Adenocarcinoma
7%
Germ Cells
7%
Patient Characteristics
6%
Surgical Resection
6%
Granulocyte Colony-stimulating Factor (G-CSF)
6%
Predictive Value
6%
Mutation Status
6%
Hepatocellular Carcinoma
6%
Immune Cells
6%
MFOLFOX6
6%
Oncologists
6%
Carcinoembryonic Antigen
6%
Expanded Access
6%
Circulating Tumor DNA (ctDNA)
6%
Immune Checkpoint Therapy
6%
Human Epidermal Growth Factor Receptor 2 (HER2)
6%
Adjuvant Chemotherapy
6%
Bevacizumab Therapy
6%
Placebo Groups
6%
Receptor Tyrosine Kinase
6%
Continuous Infusion
6%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
6%
Hispanic
6%
Clinical Benefit
6%
Tipiracil
6%
Cancer Diagnosis
6%
Esophageal Adenocarcinoma
6%
Systemic Treatment
6%
Treatment-related
6%
Histology
6%
Advanced Esophageal Cancer
6%
Disease Control
6%
FOLFIRINOX
5%
Cancer Management
5%
Genomic Profiling
5%
Tumor Immunity
5%
Phase II Clinical Trial
5%
Fluoropyrimidine
5%
Autophagy
5%
Peripheral Blood Mononuclear Cells
5%
Recurrence-free Survival
5%
Ethnic Minorities
5%
MEK Inhibitor (MEKi)
5%
Hispanic Patients
5%
Dose Expansion
5%
First-line Therapy
5%
Eastern Cooperative Oncology Group
5%
Disease Progression
5%
Therapeutic Target
5%
Biological Agents
5%
Randomized Clinical Trial
5%
Oral Administration
5%
Restaging
5%
FOLFIRI
5%
Microsatellite Stable Colorectal Cancer
5%
Safety Profile
5%
Survival Outcomes
5%
HER2-positive
5%
Stage II Colon Cancer
5%
Recurrence Risk
5%
Esophageal Cancer
5%
Gemcitabine Plus Nab-paclitaxel
5%
Young Patients
5%
Durable Response
5%
Current Treatment
5%
Organ Function
5%
Metastatic Colorectal Adenocarcinoma
5%
Cisplatin Treatment
5%
Irradiation
5%
Oral Etoposide
5%
Metastasis
5%
Concurrent Chemotherapy
5%
Transcriptomic Landscape
5%
Neoadjuvant
5%
Continuous Intravenous Infusion
5%
Native American
5%
Adenocarcinoma of the Esophagogastric Junction
5%
Malignancy
5%
Comprehensive Genomic Profiling
5%
Comorbidity
5%
Rare Cancer
5%
Downstaging
5%
Fixed Dose Rate Infusion
5%
Heat Shock Protein 90 (Hsp90)
5%
Rationally Designed
5%
Colorectal Adenocarcinoma
5%
Pancreatic Adenocarcinoma
5%
Monotherapy
5%
Treatment Trials
5%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Colorectal Cancer
88%
Colorectal Carcinoma
69%
Overall Survival
62%
Chemotherapy
60%
Solid Malignant Neoplasm
59%
Gemcitabine
54%
Neoplasm
52%
Progression Free Survival
51%
Malignant Neoplasm
51%
Diseases
50%
Bevacizumab
43%
Adverse Event
37%
Pancreas Adenocarcinoma
34%
Oxaliplatin
33%
Pancreas Cancer
31%
Irinotecan
31%
Capecitabine
29%
Fluorouracil
28%
Chemoradiation Therapy
28%
Pharmacokinetics
25%
Clinical Trial
24%
Phase II Trials
24%
Paclitaxel
22%
Cetuximab
22%
Rectum Cancer
19%
Folinic Acid
19%
Imatinib
18%
Maximum Tolerated Dose
18%
Neutropenia
18%
Placebo
17%
Tolerability
16%
Antitumor Activity
15%
Trifluridine
14%
Cisplatin
14%
Biological Marker
14%
Pembrolizumab
14%
Biliary Tract Cancer
14%
Atezolizumab
14%
Leukemia
14%
Tipiracil
13%
Phase I Trials
13%
Anemia
13%
Adenocarcinoma
12%
Diarrhea
12%
Immunotherapy
11%
Immune Checkpoint Inhibitor
11%
Prostate Cancer
10%
Docetaxel
10%
Esophageal Adenocarcinoma
10%
Randomized Controlled Trial
9%
Cyclic AMP Dependent Protein Kinase
9%
Liver Cell Carcinoma
9%
Etoposide
9%
Aurora Kinase
9%
Alisertib
9%
Digestive System Cancer
9%
Aminosalicylic Acid
9%
Ulcerative Colitis
9%
Margetuximab
9%
Isoprenaline
9%
Nausea
8%
Thrombocytopenia
8%
Leukopenia
8%
Abdominal Cancer
7%
Bilirubin
7%
Regorafenib
7%
Monoclonal Antibody
7%
Fluoropyrimidine
7%
Tumor Microenvironment
7%
Epidermal Growth Factor Receptor
7%
Colon Carcinoma
7%
Disease Exacerbation
6%
Recurrence Free Survival
6%
Prevalence
6%
Non Small Cell Lung Cancer
5%
Biological Product
5%
Granulocyte Colony Stimulating Factor
5%
Bile Duct Cancer
5%
Survival Rate
5%
Tipiracil Plus Trifluridine
5%
Carcinoembryonic Antigen
5%
Mitogen Activated Protein Kinase
5%
Randomized Clinical Trial
5%
Rectum Carcinoma
5%
Breast Cancer
5%
Folic Acid
5%
Toxicity
5%
Carboplatin
5%
Programmed Death 1 Ligand 1
5%
Mitogen Activated Protein Kinase Kinase Inhibitor
5%
Vasculotropin
5%
Medicine and Dentistry
Colorectal Carcinoma
71%
Metastatic Colorectal Cancer
69%
Overall Survival
56%
Neoplasm
55%
Malignant Neoplasm
54%
Oncology
36%
Diseases
36%
Progression Free Survival
31%
Gemcitabine
29%
Pancreas Cancer
29%
Immunotherapy
26%
Capecitabine
25%
Oxaliplatin
25%
Hazard Ratio
23%
Pancreas Adenocarcinoma
22%
Chemoradiotherapy
21%
Gene Expression
20%
Cancer
20%
Radiation Therapy
20%
Arm
19%
Rectum Cancer
19%
Immunity
19%
Pembrolizumab
19%
Biological Marker
18%
Bevacizumab
18%
Cetuximab
17%
Squamous Cell Carcinoma
17%
Systemic Therapy
16%
Clinical Trial
16%
Adenocarcinoma
15%
Placebo
15%
Phase II Trials
14%
Immune Checkpoint Inhibitor
14%
Gastrointestinal Cancer
14%
Leukemia
14%
Biliary Tract Cancer
14%
Surgery
13%
Adverse Event
12%
Targeted Therapy
12%
Recurrent Disease
11%
Paclitaxel
11%
Esophageal Adenocarcinoma
11%
Colon
10%
Microsatellite Instability
10%
Colon Carcinoma
10%
Abdominal Cancer
10%
Primary Tumor
10%
Solid Malignant Neoplasm
10%
Immunocompetent Cell
10%
Metastatic Carcinoma
9%
Colorectal Liver Metastasis
9%
Hepatocellular Carcinoma
9%
Cyclic AMP Dependent Protein Kinase
9%
Aurora Kinase
9%
Alisertib
9%
Chemoradiation Therapy
9%
FOLFOX
9%
Randomized Controlled Trial
9%
Pancreas Carcinoma
9%
Myeloid Cell
9%
Racial Disparity
9%
Anemia
8%
Tumor Microenvironment
8%
Decision Making
8%
Patient Population
8%
T Cell
8%
Bilirubin
7%
Fluorouracil
7%
Prevalence
7%
Monoclonal Antibody
7%
Molecular Profiling
7%
Retrospective Cohort Study
7%
Quality of Life
7%
Proportional Hazards Model
6%
Cancer Therapy
6%
Cancer Diagnosis
6%
Survival Analysis
6%
Programmed Death 1 Ligand 1
6%
Recurrence Free Survival
6%
Leukopenia
6%
Transcriptomics
6%
Infusion
6%
Systematic Review
6%
Anal Cancer
6%
Germ Cell
6%
Thrombocytopenia
6%
Oncologist
5%
Adjuvant Chemotherapy
5%
DNA Mismatch Repair
5%
Randomized Clinical Trial
5%
Bile Duct Cancer
5%
Biliary Duct Cancer
5%
Survival Rate
5%
DNA Repair
5%
Carcinoembryonic Antigen
5%
Antineoplastic Activity
5%
Next Generation Sequencing
5%
Esophageal Cancer
5%
Triple Negative Breast Cancer
5%
Radioembolization
5%
Toxicity
5%
Disease Exacerbation
5%
Carboplatin
5%
Progressive Disease
5%
Gene Mutation
5%
MEK Inhibitor
5%
Comprehensive Genomic Profiling
5%
Patient Characteristics
5%
Regorafenib
5%
Neutropenia
5%